Loading article
Conditions
How allergic rhinitis affects more than 6 million Australians, what triggers symptoms, and what the evidence says about treatment.
This article is for general information and does not constitute medical advice. Treatment decisions are made by an AHPRA-registered doctor after reviewing your circumstances.
According to the Australian Institute of Health and Welfare (AIHW), allergic rhinitis (hay fever) affected around 6.1 million Australians in 2022, or nearly 24% of the population. It is one of the most prevalent chronic respiratory conditions in the country. Despite being widely regarded as a minor inconvenience, hay fever can impair sleep, concentration, work, study, exercise, and quality of life, and it is closely linked with asthma in some people.
Allergic rhinitis is an IgE-mediated hypersensitivity reaction in the nasal mucosa. When a sensitised person inhales an allergen - pollen, dust mite, pet dander, or mould - the immune system releases histamine and other mediators. These cause the classic symptoms: nasal congestion, rhinorrhoea, sneezing, and itching.
ASCIA distinguishes two patterns:
Many Australians have both patterns - seasonal triggers on top of a perennial baseline.
Hay fever triggers vary by region, season, home environment, and personal sensitisation pattern.
Australian pollen monitoring services can help people anticipate high-risk days. On forecast high-pollen days, taking planned treatment before predictable exposure is often more useful than waiting until symptoms are severe.
Allergic rhinitis symptoms reflect inflammation of the nasal mucosa and, frequently, the conjunctiva:
Technique
Aiming slightly outward can improve effect and reduce irritation compared with spraying straight up the septum.
An important distinction from common cold: hay fever does not cause fever, body aches, or productive cough. If those symptoms are present, a viral infection is the more likely diagnosis. ASCIA notes that misidentifying colds as hay fever (and vice versa) is common and leads to inappropriate self-treatment.
Formal diagnosis is typically clinical, based on symptom history, trigger pattern, examination where needed, and response to treatment. Allergy testing (skin prick test or allergen-specific IgE blood testing) confirms sensitisation and is useful when immunotherapy is being considered, when the trigger is unclear, or when symptoms are persistent despite reasonable management.
Australian primary-care and allergy guidance supports a stepwise approach to treatment, starting with exposure reduction and pharmacy options, then escalating if symptoms are not controlled or if asthma, sleep, or daily function is affected.
Treatment choice depends on dominant symptoms, severity, timing, and whether asthma is also present.
Intranasal corticosteroid sprays, including fluticasone propionate, mometasone, and budesonide, are a key treatment class for moderate-to-severe symptoms, particularly nasal blockage. Healthdirect and ASCIA note that these sprays work best when used consistently, not only after symptoms have become severe.
ASCIA and RACGP recommend second-generation antihistamines such as cetirizine, loratadine, and fexofenadine over first-generation antihistamines such as promethazine because of the superior safety profile and lower risk of significant sedation.
ASCIA, healthdirect, and asthma guidance identify allergic rhinitis as a risk factor for asthma symptoms and asthma exacerbations. This is often described as the "united airway" concept - the upper and lower airways share related inflammatory pathways. In practical terms, uncontrolled hay fever can worsen asthma symptoms, and asthma symptoms during pollen season should not be dismissed as "just allergies".
For people with both conditions, treating hay fever well is part of asthma management. ASCIA recommends that all patients with asthma be assessed for allergic rhinitis, and vice versa.
Important warning
For patients with confirmed allergen sensitisation whose symptoms are not adequately controlled with medications, ASCIA recommends consideration of allergen immunotherapy (AIT). AIT works by gradually desensitising the immune response through repeated, escalating doses of the allergen.
Two forms are available in Australia:
Control stack
Exposure reduction, correct spray use, and allergy medicines each solve a different part of the problem.
Both have strong evidence for reducing both rhinitis and asthma symptoms, and for preventing progression of rhinitis to asthma. The TGA has approved several SLIT products for grass pollen, the most common allergen trigger in Australia. AIT requires specialist assessment (allergist or immunologist) and is not appropriate for all patients.
Seek medical review if:
Seek urgent care if you experience:
Practical measures based on ASCIA guidance:
Red flags
Wheeze, chest tightness, shortness of breath, or persistent cough during pollen season need an asthma safety plan.
These measures complement medication but rarely eliminate symptoms alone in moderately sensitive individuals.
Occasional reflux is common, but frequent heartburn, regurgitation, swallowing symptoms, chest pain, bleeding signs, or persistent vomiting need a more careful plan.
Stress and burnout overlap, but they are not the same. Learn the practical differences, common warning signs, workplace drivers, recovery steps, and when to seek professional support.
Conjunctivitis is common, but not every red eye is routine pink eye. Discharge, itch, contact lens use, pain, light sensitivity, and vision change determine the safest next step.